Related Experiment Video
Updated: Jul 11, 2025
06:31
Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis
Published on: October 6, 2023
2.2K
Decision Impact Analysis to Measure the Influence of Molecular Signature Response Classifier Testing on Treatment
Jeffrey R Curtis1, Vibeke Strand2, Steven J Golombek3
1Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, USA.
Rheumatology and Therapy
|November 10, 2023
Summary
The molecular signature response classifier (MSRC) guides rheumatoid arthritis (RA) treatment selection. Most physicians used MSRC results for biologic and targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) choices, improving precision medicine in RA care.
Area of Science:
- Rheumatology
- Precision Medicine
- Clinical Decision Support
Background:
- Limited guidance exists for selecting treatments after conventional synthetic disease-modifying antirheumatic drug (csDMARD) failure in rheumatoid arthritis (RA).
- A molecular signature response classifier (MSRC) was validated to predict inadequate response to tumor necrosis factor inhibitors (TNFi).
Purpose of the Study:
- To evaluate the impact of MSRC results on the selection of biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in RA patients.
- To assess physician utilization of MSRC for treatment decisions.
Main Methods:
- Analysis of the AIMS longitudinal, prospective RA patient database.
- Physician surveys on b/tsDMARD class selection post-MSRC testing.
- Assessment of MSRC-aligned b/tsDMARD prescription rates and physician decision-making.
Main Results:
- 70.7% of patients had treatment selected after MSRC results.
- 75.6% of patients received MSRC-aligned b/tsDMARDs, with 84.6% of providers reporting MSRC use for guidance.
- Health insurance coverage was the primary reason for non-alignment (8.2%).
Conclusions:
- Rheumatologists reported using MSRC to guide b/tsDMARD selection in RA patients.
- MSRC results influenced clinical decision-making in most reported cases.
- Wider adoption of MSRC could enhance precision medicine and patient outcomes in RA.
